HER2 therapies and gastric cancer: A step forward

Mello, Ramon Andrade de; A, Marqués; Araújo, António

doi:10.3748/wjg.v19.i37.6165

Cited by 44 publications

(31 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The ToGA (trastuzumab for gastric cancer) randomized trial demonstrated a higher response rate (13-8 months) in a group of advanced gastric cancer patients with HER2--positive that received trastuzumab in combination with chemotherapy vs. chemotherapy alone (11-1 months). Other studies confirm that the combination of trastuzumab or pertuzumab with standard chemotherapy prolongs PFS and OS in HER2-positive patients [36][37][38][39].…”

Section: The Significance Of Fish Analysis In Qualification For Anti-mentioning

confidence: 74%

“…Moreover, it has been reported that dacomitinib -pan-HER inhibitor can be used in the effective treatment of gastric cancer. Till now, it has not been strictly defined which method of HER2 disorder determination should be carried out in the correct qualification of patients for trastuzumab therapy [34,[36][37][38][39].…”

Section: The Significance Of Fish Analysis In Qualification For Anti-mentioning

confidence: 99%

See 1 more Smart Citation

Detection of Chromosomal Abnormalities with Different In Situ Hybridisation Techniques - the Usefulness in Cancer Patients Qualification for Molecularly-Targeted Therapies

Nicoś¹,

Wojas‐Krawczyk²,

Krawczyk³

et al. 2015

Adv Clin Exp Med

View full text Add to dashboard Cite

Proper qualification of patients with cancer for an effective treatment regiment is essential to rationalize therapy benefit and costs. The early detection of genetic disorders that are responsible for the stimulation of uncontrolled cancer cells proliferation makes it possible to select a group of patients with a high probability of response to molecularly-targeted therapy. Data has shown that careful analysis of genes mutation using different PCR and sequencing techniques or chromosomal aberrations using in situ hybridization (ISH) techniques have a predictive value for drug targeted therapy. Overexpression of receptors and gene amplification has been reported in various cancers. Their detection is still a considerable challenge, which is connected with the unsatisfactory quality of DNA and low mutated cells percentage compared to cells with no genetic abnormalities in tested material. Different techniques of standardization were performed to prevent false negative results and to increase the sensitivity of qualitative and quantitative evaluation of chromosomal abnormalities. Immunohistochemistry (IHC) technique is useful in the screening of receptor expression in paraffin-embedded tissue samples in different malignant diseases. Whereas ISH techniques, especially fluorescence in situ hybridization (FISH), are now considered the diagnostic gold standard method in detection chromosomal aberrations. Moreover, molecular biology techniques, which are using molecular probes and real-time PCR and quantitative PCR techniques, were also applied for the detection of chromosomal changes. In order to identify the best genetic marker for treatment regiment, it is important to compare results of different studies, which are evaluating the sensitivity of diagnostic techniques and treatment response after a suitable selection factors based on genetic aberrations profile (Adv Clin Exp Med 2015, 24, 4, 715-723).

show abstract

Section: The Significance Of Fish Analysis In Qualification For Anti-mentioning

confidence: 74%

Section: The Significance Of Fish Analysis In Qualification For Anti-mentioning

confidence: 99%

Detection of Chromosomal Abnormalities with Different In Situ Hybridisation Techniques - the Usefulness in Cancer Patients Qualification for Molecularly-Targeted Therapies

Nicoś¹,

Wojas‐Krawczyk²,

Krawczyk³

et al. 2015

Adv Clin Exp Med

View full text Add to dashboard Cite

show abstract

“…Trastuzumab, a human epidermal growth factor receptor type 2 (HER2) monoclonal antibody, was the first such agent receiving Food and Drug Administration (FDA) and European Medicine Agency (EMA) approval because it was shown to improve overall response rate (ORR), progression free survival (PFS), and overall survival (OS) when added to cisplatin-based chemotherapy in patients with HER2 over-expressing GC [12][13][14][15]. However, HER2 over-expressing tumors represent approximately 20% of the total numbers of GC cases, and the need for additional targeted agents is urgent [13][14][15].…”

Section: Introductionmentioning

confidence: 99%

c-Met targeting in advanced gastric cancer: An open challenge

et al. 2015

View full text Add to dashboard Cite

“…İlerlemiş ve metastatik mide ve gastroözofageal bileşke kanserlerinde kombine kemoterapi ve trastuzumab tedavisiyle, tek başına kemoterapiye göre sağkalım avantajının gösterilmesi, trastuzumabı mide kanserlerinde de tedavi seçeneği haline getirmiştir (7). Bu gelişmeyle birlikte günlük pratikte tüm yeni tanı alan mide kanserlerinde de HER2 İHK testi yapılması önerilir hale gelmiştir (26).…”

unclassified

HER2 Assessment in Gastric Carcinoma

Irkkan¹

2014

Acta Oncol Tur.

View full text Add to dashboard Cite

ÖZETİlerlemiş mide ve gastroözofageal bileşke karsinomlarında tedaviye Trastuzumab eklenmesi, Her2 pozitif tümörlü hastalarda sağkalım avantajı sağlamıştır. Bu tedaviden faydalanabilecek hastaların Her2 testi ile belirlenmesi gerekmektedir. Meme karsinomlarından sonra, mide karsinomlarında da Her2 testi patoloji laboratuarlarının günlük işleri arasına girmiştir. Mide karsinomlarında Her2 testi, meme karsinomlarındakine benzer özellikler içermekle birlikte, bilinmesi gereken farklı yönleri de vardır. Bu farklar, başlıca mide karsinomlarında Her2 pozitifliğinin daha heterojen olması ve karsinom hücre membranlarında, reseptörlerin bazolateral yerleşimlerinden kaynaklanmaktadır. Her2 testinde kullanılan immünhistokimyasal ve in situ hibridizasyon testleri, çoğu laboratuarda kullanılır testler arasında olmakla birlikte, skorlama kriterleri karışıktır ve doğru sonuç için deneyim gerektirmektedir. Bu testlerde doğruluğu sağlamak için analitik koşullar kadar preanalitik koşullar da etkilidir. Anahtar Kelimeler: Mide neoplazmları, HER2ABSTRACT Addition of Trastuzumab in treatment of advanced gastric and gastroesophageal carcinomas has provided benefits in overall survival of those with Her2 positive tumors. It is necessary to identify patients who can benefit from the treatment with Her2 test. Following breast carcinomas, Her2 testing in gastric carcinomas are also added to the routine work of pathology labs. Although Her2 test in gastric carcinomas has similar features with that of breast, it has some aspects to be known well. These aspects have arisen mainly because of heterogeneous Her2 positivity and basolateral settling of the receptors in gastric carcinoma cells. Although Her2 immunohistochemical and in situ hybridization tests are among routine tests of most laboratories, scoring criteria are complex and need experience for accurate results. In achieving accurate results in these tests, pre-analytical as well as the analytical conditions, are also effective.

show abstract

HER2 therapies and gastric cancer: A step forward

Cited by 44 publications

References 42 publications

Detection of Chromosomal Abnormalities with Different In Situ Hybridisation Techniques - the Usefulness in Cancer Patients Qualification for Molecularly-Targeted Therapies

Detection of Chromosomal Abnormalities with Different In Situ Hybridisation Techniques - the Usefulness in Cancer Patients Qualification for Molecularly-Targeted Therapies

c-Met targeting in advanced gastric cancer: An open challenge

HER2 Assessment in Gastric Carcinoma

Contact Info

Product

Resources

About